1 documents found
Information × Registration Number 0212U004840, 0109U000439 , R & D reports Title To optimize the treatment of patients with Hodgkin's lymphoma from the high risk group (multicentral research) popup.stage_title Head Кryachok I, Registration Date 06-02-2012 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of research - 202 Hodgkin's high risk lymphoma patients. Purpose - to improve treatment of primary Hodgkin's lymphoma high risk patients by choosing the most effective combinations chemoregimens. Methods and equipments: morphological, immunohistochemistry, clinical, statisticsl, ultrasonic apparatus "Aloca", CT. A treatment of 151 patients with high risk Hodgkin's lymphoma patients (HL) for the designed protocol, 32 patients were included in the study from other institutions (Cherkassy, Poltava, Zhytomyr, Kherson Oncology Center,City Clinical Hospital № 25, Kharkiv, Kyiv Regional Oncology Center). Analyzed the treatment of 51 high risk patients with HL who received ABVD.It was found that treatment of high risk patients with HL with BEASOPP-14 and BEASOPP-ESC is highly effective (efficacy is 95.32 and 94.29%, respectively). The overall effectiveness of treatment of high isk HL patients with ABVD is much 80.39%. It was revealed that the toxicity of BEACOPP-ESC higher than BEACOPP-ESC, therapy is often complicated by anemia (63.18% vs. 54.25%), neutropenia (72.33% vs. 62.09%) and thrombocytopenia (27.65% vs. 19.9%). In BEACOPP-ESC group infections are more frequently observed (13.09% vs. 4.47%). Assign maintenance therapy CSF and erythropoietin can not violate the protocol treatment. Overall 2-year survival in BEACOPP-ESC was 95.55% in group BEACOPP-14 - 100% progression-free survival rate of 90.01% and 95.09%, respectively.The predictive value of gene polymorphism of glutathione-S-transferase P1 was avaluate in 96 patients with Hodgkin's lymphoma and no соrrelation between GSTP1 gene polymorphism and risk of Hodgkin's lymphoma was found. But the GSTP1 gene polymorphism has an influence on the clinical course of disease: homozygous inheritance wild type allele is associated with higher aggressiveness course of Hodgkin's lymphoma, which can be used as a prognostic factor in Hodgkin's lymphoma patients. Product Description popup.authors Лялькін Сергій Анатолійович Майданевич Наталья Миколаївна Мартинчик Арина Валеріївна Новосад Ольга Ігоревна Титоренко Ірина Борисівна Яценко Людмила Дмитріївна popup.nrat_date 2020-04-02 Close
R & D report
Head: Кryachok I. To optimize the treatment of patients with Hodgkin's lymphoma from the high risk group (multicentral research). (popup.stage: ). Ukrainian Research Institute of Oncology and Radiology. № 0212U004840
1 documents found

Updated: 2026-03-22